Acrivon Therapeutics Common Stock Performance
| ACRV Stock | 9.39 1.15 10.91% |
Acrivon Therapeutics holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.51, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Acrivon Therapeutics will likely underperform. Use Acrivon Therapeutics value at risk, as well as the relationship between the kurtosis and price action indicator , to analyze future returns on Acrivon Therapeutics.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Acrivon Therapeutics Common are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Acrivon Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.93 | Five Day Return 14.44 | Year To Date Return 110.38 | Ten Year Return 105.4 M | All Time Return 105.4 M |
1 | Acquisition by Magovcevicliebisch Ivana of 32500 shares of Acrivon Therapeutics subject to Rule 16b-3 | 02/09/2024 |
2 | Disposition of 217 shares by Miller Mary of Acrivon Therapeutics at 3.4 subject to Rule 16b-3 | 02/16/2024 |
3 | Insider Trading | 03/06/2024 |
4 | Acrivon Therapeutics and Avid Bioservices Critical Review | 03/11/2024 |
5 | Acrivon Therapeutics, Inc. Given Average Recommendation of Buy by Analysts - MarketBeat | 03/26/2024 |
6 | ACRV Stock Earnings Acrivon Therapeutics Misses EPS for Q4 2023 | 03/28/2024 |
7 | Acrivon Therapeutics Given Market Outperform Rating at JMP Securities - Defense World | 04/02/2024 |
8 | Acquisition by Eric Devroe of 9225 shares of Acrivon Therapeutics at 1.04 subject to Rule 16b-3 | 04/05/2024 |
9 | Crude Oil Down Over 1 Cognyte Software Shares Plummet | 04/09/2024 |
10 | Acquisition by Perceptive Advisors Llc of 2353000 shares of Acrivon Therapeutics at 8.5 subject to Rule 16b-3 | 04/11/2024 |
11 | Acrivon Therapeutics to Host Corporate RD Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with I... | 04/17/2024 |
| Begin Period Cash Flow | 29.5 M |
Acrivon |
Acrivon Therapeutics Relative Risk vs. Return Landscape
If you would invest 448.00 in Acrivon Therapeutics Common on January 20, 2024 and sell it today you would earn a total of 606.00 from holding Acrivon Therapeutics Common or generate 135.27% return on investment over 90 days. Acrivon Therapeutics Common is currently generating 1.8391% in daily expected returns and assumes 10.7436% risk (volatility on return distribution) over the 90 days horizon. In different words, 94% of stocks are less volatile than Acrivon, and 64% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acrivon Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acrivon Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acrivon Therapeutics Common, and traders can use it to determine the average amount a Acrivon Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1712
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ACRV | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.74 actual daily | 94 94% of assets are less volatile |
Expected Return
| 1.84 actual daily | 36 64% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Acrivon Therapeutics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acrivon Therapeutics by adding it to a well-diversified portfolio.
Acrivon Therapeutics Fundamentals Growth
Acrivon Stock prices reflect investors' perceptions of the future prospects and financial health of Acrivon Therapeutics, and Acrivon Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acrivon Stock performance.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 111.25 M | ||||
| Shares Outstanding | 30.87 M | ||||
| Price To Book | 2.54 X | ||||
| EBITDA | (66.7 M) | ||||
| Net Income | (60.39 M) | ||||
| Total Debt | 4.64 M | ||||
| Book Value Per Share | 5.38 X | ||||
| Cash Flow From Operations | (42.64 M) | ||||
| Earnings Per Share | (2.74) X | ||||
| Market Capitalization | 319.22 M | ||||
| Total Asset | 138.26 M | ||||
| Retained Earnings | (116.42 M) | ||||
| Working Capital | 116.39 M | ||||
About Acrivon Therapeutics Performance
To evaluate Acrivon Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Acrivon Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Acrivon Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Acrivon Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Acrivon's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.54) | (0.56) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.50) | (0.47) |
Things to note about Acrivon Therapeutics performance evaluation
Checking the ongoing alerts about Acrivon Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acrivon Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acrivon Therapeutics is way too risky over 90 days horizon | |
| Acrivon Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (60.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acrivon Therapeutics generates negative cash flow from operations | |
| Acrivon Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: Acrivon Therapeutics to Host Corporate RD Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 |
- Analyzing Acrivon Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acrivon Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Acrivon Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acrivon Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acrivon Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acrivon Therapeutics' stock. These opinions can provide insight into Acrivon Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acrivon Therapeutics Common. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Acrivon Stock analysis
When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |
Is Acrivon Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acrivon Therapeutics. If investors know Acrivon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acrivon Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.74) | Return On Assets (0.26) | Return On Equity (0.41) |
The market value of Acrivon Therapeutics is measured differently than its book value, which is the value of Acrivon that is recorded on the company's balance sheet. Investors also form their own opinion of Acrivon Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acrivon Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acrivon Therapeutics' market value can be influenced by many factors that don't directly affect Acrivon Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acrivon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acrivon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acrivon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.